Markets
Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tablets
Concord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approval for rheumatoid arthritis and other conditions is expected to bolster its U.S.
Concord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approval for rheumatoid arthritis and other conditions is expected to bolster its U.S.
market presence and product portfolio, targeting a $500 million market opportunity.
Source reference: Economic Times
Australian shares rebounded on Wednesday, driven by gains in banks and consumer stocks, as softer economic data eased rate hike expectations. The S&P/ASX 200 index rose 0.6%, with markets now pricing in earlier rate cuts
Retail chains from smaller Indian towns are planning to raise over Rs 7,000 crore through IPOs. These companies see capital markets as a fast route to fund expansion into growing markets beyond metros. This trend reflect
Indian banks are significantly increasing rates on foreign-currency deposits to attract overseas residents, testing the central bank's new measures to boost capital inflows and support the rupee. This strategy aims to st
This article is not yet linked to a specific live market instrument.
Why it matters
Rupixa articles now connect headlines to live instruments where possible so readers can move from a headline into the affected market surface without losing context.